Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small ...
In 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was approved. The drug, known as ipilimumab or Yervoy, stood apart from standard cancer treatments. It worked by ...
Using less ipilimumab appears to make melanoma immunotherapy both safer and more effective, with dramatically better response and survival outcomes. The findings suggest that reducing side effects may ...
There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in ...
Trend and Provider- and Organizational-Level Factors Associated With Early Palliative Care Billing Among Patients Diagnosed With Distant-Stage Cancers in 2010-2019 in the United States Patients with ...
A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...
BOSTON — All cancer patients receiving treatment with the immune checkpoint inhibitor ipilimumab (Yervoy, Bristol-Myers Squibb) should be closely monitored for signs and symptoms of hypophysitis, new ...
The effect of ipilimumab on overall survival and distant metastasis–free survival is important, given that the only other approved systemic therapy in the context of adjuvant therapy, interferon alfa, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results